Table of Contents
Sequencing
Volume 2011, Article ID 895709, 7 pages
http://dx.doi.org/10.1155/2011/895709
Research Article

KRAS Codons 12 and 13 Mutation Analysis: A Comparative Study between Direct Sequencing and a New Sensitive Real-Time PCR Assay

1Dipartimento di Scienze Mediche e Biologiche, Università di Udine, 33100 Udine, Italy
2AB ANALITICA s.r.l., 35127 Padova, Italy

Received 29 July 2011; Revised 26 September 2011; Accepted 29 September 2011

Academic Editor: Luis Menéndez-Arias

Copyright © 2011 Stefania Marzinotto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Di Fiore, F. Blanchard, F. Charbonnier et al., “Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy,” British Journal of Cancer, vol. 96, no. 8, pp. 1166–1169, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. F. Molinari, L. Felicioni, M. Buscarino et al., “Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer,” Clinical Cancer Research, vol. 17, no. 14, pp. 4901–4914, 2011. View at Publisher · View at Google Scholar · View at PubMed
  3. A. Sartore-Bianchi, K. Bencardino, A. Cassingena et al., “Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer,” Cancer Treatment Reviews, vol. 36, no. 3, pp. S1–S5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. H. J. M. Van Krieken, A. Jung, T. Kirchner et al., “KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program,” Virchows Archiv, vol. 453, no. 5, pp. 417–431, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. B. George and S. Kopetz, “Predictive and prognostic markers in colorectal cancer,” Current Oncology Reports, vol. 13, no. 3, pp. 206–215, 2011. View at Publisher · View at Google Scholar · View at PubMed
  6. D. L. Worthley, V. L. Whitehall, K. J. Spring, and B. A. Leggett, “Colorectal carcinogenesis: road maps to cancer,” World Journal of Gastroenterology, vol. 13, no. 28, pp. 3784–3791, 2007. View at Google Scholar · View at Scopus
  7. C. S. Karapetis, S. Khambata-Ford, D. J. Jonker et al., “K-ras mutations and benefit from cetuximab in advanced colorectal cancer,” New England Journal of Medicine, vol. 359, no. 17, pp. 1757–1765, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. F. Kabbinavar, H. I. Hurwitz, L. Fehrenbacher et al., “Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 21, no. 1, pp. 60–65, 2003. View at Google Scholar · View at Scopus
  9. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. L. B. Saltz, N. J. Meropol, P. J. Loehrer, M. N. Needle, J. Kopit, and R. J. Mayer, “Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1201–1208, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. R. G. Amado, M. Wolf, M. Peeters et al., “Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1626–1634, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. E. van Cutsem, C. H. Köhne, E. Hitre et al., “Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer,” New England Journal of Medicine, vol. 360, no. 14, pp. 1408–1417, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. A. Lièvre, H. Blons, and P. Laurent-Puig, “Oncogenic mutations as predictive factors in colorectal cancer,” Oncogene, vol. 29, no. 21, pp. 3033–3043, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer,” New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. G. Schuch, S. Kobold, and C. Bokemeyer, “Evolving role of cetuximab in the treatment of colorectal cancer,” Journal of Cancer Management and Research, vol. 1, pp. 79–88, 2009. View at Google Scholar
  16. G. Tonini, A. Calvieri, B. Vincenzi, and D. Santini, “First-line targeted therapies in the treatment of metastatic colorectal cancer - Role of cetuximab,” OncoTargets and Therapy, vol. 2, pp. 73–82, 2009. View at Google Scholar · View at Scopus
  17. A. Sartore-Bianchi, F. Di Nicolantonio, M. Nichelatti et al., “Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer,” PLoS ONE, vol. 4, no. 10, Article ID e7287, 2009. View at Publisher · View at Google Scholar · View at PubMed
  18. R. Reddavide, G. Misciagna, M. G. Caruso et al., “Tissue expression of glycated apolipoprotein B in colorectal adenoma and cancer,” Anticancer Research, vol. 31, no. 2, pp. 555–559, 2011. View at Google Scholar
  19. D. L. Wheeler, E. F. Dunn, and P. M. Harari, “Understanding resistance to EGFR inhibitors-impact on future treatment strategies,” Nature Reviews Clinical Oncology, vol. 7, no. 9, pp. 493–507, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. A. Bardelli and S. Siena, “Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1254–1261, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. Frattini, G. Gallino, S. Signoroni et al., “Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool,” Annals of the New York Academy of Sciences, vol. 1075, pp. 185–190, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. B. Angulo, E. García-García, R. Martínez et al., “A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma,” Journal of Molecular Diagnostics, vol. 12, no. 3, pp. 292–299, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. W. De Roock, B. Claes, D. Bernasconi et al., “Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis,” The Lancet Oncology, vol. 11, no. 8, pp. 753–762, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S. M. Anderson, “Laboratory methods for KRAS mutation analysis,” Expert Review of Molecular Diagnostics, vol. 11, no. 6, pp. 635–642, 2011. View at Publisher · View at Google Scholar · View at PubMed
  25. A. C. Tsiatis, A. Norris-Kirby, R. G. Rich et al., “Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications,” Journal of Molecular Diagnostics, vol. 12, no. 4, pp. 425–432, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. Z. Zuo, S. S. Chen, P. K. Chandra et al., “Application of COLD-PCR for improved detection of KRAS mutations in clinical samples,” Modern Pathology, vol. 22, no. 8, pp. 1023–1031, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. P. Nollau and C. Wagener, “Methods for detection of point mutations: performance and quality assessment. The IFCC Scientific Division, Committee on Molecular Biology Techniques,” Journal of the International Federation of Clinical Chemistry, vol. 9, no. 4, pp. 162–170, 1997. View at Google Scholar · View at Scopus
  28. J. H. J. M. van Krieken, A. Jung, T. Kirchner et al., “KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program,” Virchows Archiv, vol. 453, no. 5, pp. 417–431, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. W. A. Franklin, J. Haney, M. Sugita, L. Bemis, A. Jimeno, and W. A. Messersmith, “KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer,” Journal of Molecular Diagnostics, vol. 12, no. 1, pp. 43–50, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. A. Jimeno, W. A. Messersmith, F. R. Hirsch, W. A. Franklin, and S. G. Eckhardt, “KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer,” Cancer Journal, vol. 15, no. 2, pp. 110–113, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. N. Thelwell, S. Millington, A. Solinas, J. Booth, and T. Brown, “Mode of action and application of Scorpion primers to mutataon detection,” Nucleic Acids Research, vol. 28, no. 19, pp. 3752–3761, 2000. View at Google Scholar · View at Scopus